[_ES5] 英語口演5
新規治療・萌芽的研究

English Session 5　New treatment・Exploratory research

2018年11月16日(金) 08:20 〜 09:20 第1会場 (みやこめっせ 1F 第2展示場D)

座長:平松英文（京都大学大学院医学研究科発達小児科学）, 高木正稔（東京医科歯科大学大学院医歯学総合研究科発生発達病態学分野）

+全てマイスケジュールに登録

[ES5-3-1] 臨床的意義不明のがん素因遺伝子変異に対する機能的評価の研究
Functional Evaluation of Unclassified Variants Identified in Cancer Predisposition Genes

Kayoko Tao (Department of Pediatrics, University of Tsukuba Hospital)

[ES5-3-2] がん診療におけるゲノム情報を用いた医療実現のためのTOP-GEARプロジェクト：小児がん患者における解析
TOP-GEAR project for implementation of clinical sequencing in cancer clinic: analysis of patients with pediatric cancer

Chitose Ogawa¹, Tadashi Kumamoto¹, Ayumu Arakawa¹, Kuniko Sunami^2,3, Yutaka Fujiwara⁴, Takashi Kubo^5,6, Hitoshi Ichikawa^5,6, Takashi Kohno^3,5, Noboru Yamamoto⁴ (1.Department of Pediatric Oncology, National Cancer Center Hospital, 2.Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, 3.Division of Genome Biology, National Cancer Center Research Institute, 4.Department of Experimental Therapeutics, National Cancer Center Hospital, 5.Division of Translational Genomics, National Cancer Center EPOC, 6.Department of Clinical Genomics, National Cancer Center Research Institute)

[ES5-3-3] NKp44-CAR-T細胞の抗腫瘍効果：活性化NK細胞およびNKp30-CAR-T細胞との比較検討
Superior Activity of NKp44-CAR-T Cells in Comparison with Ex Vivo Expended Activated NK cells or NKp30-CAR-T cells

Yasushi Kasahara, Chansu Shin, Nobuhiro Kubo, Haruko Iwabuchi, Masaru Imamura, Akihiko Saitoh, Chihaya Imai (Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan)

[ES5-3-4] PD-1とCTLA4両シグナルを抑制する新規免疫チェックポイント阻害剤の開発
A novel drug candidate inducing tumor cell death and both PD-1 and CTLA4 pathways blockade in tumor environment

Hiroki Nagase^1,2, Keiko Fukushima³, Asuka Hattori², Mayu Shinohara², Atsushi Takatori¹, Takayoshi Watanabe¹, Nobuko Koshikawa¹, Takahiro Inoue², Jason Lin¹, Yoshinao Shinozaki¹ (1.Chiba Cancer Center Research Institute, 2.Department of Molecular Biology and Oncology, Chiba University School of Medicine, 3.Zenyaku Kogyo Co., Ltd,)

[ES5-3-5] 化学療法中の卵巣予備能・妊孕性温存のための新規治療の開発：ミュラー管抑制因子の応用
Concurrent Mullerian inhibiting Substance therapy during chemotherapy preserves the ovarian reserve and fertility

Motohiro Kano^1,2, Lihua Zhang², Hatice Saatcioglu², Nicholas Nagykery², Tatsuo Kuroda¹, Patricia Donahoe², David Pepin² (1.Department of Pediatric Surgery, Keio University School of Medicine, Tokyo, Japan, 2.Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Boston, MA United States)

セッション情報

[_ES5] 英語口演5新規治療・萌芽的研究

English Session 5 New treatment・Exploratory research

[ES5-3-1] 臨床的意義不明のがん素因遺伝子変異に対する機能的評価の研究Functional Evaluation of Unclassified Variants Identified in Cancer Predisposition Genes

[ES5-3-2] がん診療におけるゲノム情報を用いた医療実現のためのTOP-GEARプロジェクト：小児がん患者における解析TOP-GEAR project for implementation of clinical sequencing in cancer clinic: analysis of patients with pediatric cancer

[ES5-3-3] NKp44-CAR-T細胞の抗腫瘍効果：活性化NK細胞およびNKp30-CAR-T細胞との比較検討Superior Activity of NKp44-CAR-T Cells in Comparison with Ex Vivo Expended Activated NK cells or NKp30-CAR-T cells

[ES5-3-4] PD-1とCTLA4両シグナルを抑制する新規免疫チェックポイント阻害剤の開発A novel drug candidate inducing tumor cell death and both PD-1 and CTLA4 pathways blockade in tumor environment